The pandemic has given us the opportunity to reclaim our spot in the APIs market and not repeat the mistakes of the past
In Conversation
Our view is that all stakeholders – not just payers – have responsibility for ensuring access, meaning that building on strong collaborations and public-private partnerships will be…
Two LatAm countries – Colombia and Mexico – are [MSD's] top clinical trial patient enrollers worldwide, and LatAm makes up approximately 15 percent of our total…
Despite the uncertainty of [LatAm] markets - due to inflation, political issues or even social ones - these challenges are what make us stronger and perform…
Healthcare sustainability depends on breaking down silos, bringing all stakeholders together with the patient at the centre to deliver mutual benefit. If the patient – who…
In a complex and fast-changing environment like LatAm, there are many roadblocks to execution depending on the country, geography, or political environment. We must therefore be…
Real value comes from bringing stakeholders from the pharma, medtech, and technology industries together to create the health systems of the future
Brazil is now being considered as an end-to-end country in which to engage in clinical trials. An example I can give is the primary research we…
Our job in LatAm is to ensure that the population in general, as well as healthcare providers and governments, understand the importance of diagnosing and treating…
Five of the 16 countries that together account for 85 percent of the growth of [GSK's emerging markets] region are from Latin America
Access to medication is at the company’s core; what we do is ensure scale gain so that we can have competitive costs and prices
"In the pharmaceutical industry, market access has become a crucial area for several decades already, and the continuous development and refinement of these capacities are truly…
